Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:52:32.229Z.
Calculation as of: 2026-10-06T18:52:32.229Z.
Quote observation: 2026-10-06T18:49:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d71c6897c98d436948f76d79272a6a7ae3c560285f8867db41996dc6a6301e16
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$58.59M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$58.16M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oncolytics Biotech Inc. (ONCY) | $59.76M | N/A | N/A | N/A | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.03M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.94M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $61.87M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $59.41M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.55M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $58.59M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $58.32M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $58.16M | N/A | N/A | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.50M | N/A | 0.88% | 0.88% | 0.88% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
